MX2024001954A - Anticuerpos il-13 para el tratamiento de la dermatitis atopica. - Google Patents

Anticuerpos il-13 para el tratamiento de la dermatitis atopica.

Info

Publication number
MX2024001954A
MX2024001954A MX2024001954A MX2024001954A MX2024001954A MX 2024001954 A MX2024001954 A MX 2024001954A MX 2024001954 A MX2024001954 A MX 2024001954A MX 2024001954 A MX2024001954 A MX 2024001954A MX 2024001954 A MX2024001954 A MX 2024001954A
Authority
MX
Mexico
Prior art keywords
antibodies
atopic dermatitis
treatment
methods
treating atopic
Prior art date
Application number
MX2024001954A
Other languages
English (en)
Inventor
Eugene A Bauer
Janice Suzann Drew
Renata Gontijo Lima
Jennifer Wright Witcher
Original Assignee
Dermira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermira Inc filed Critical Dermira Inc
Publication of MX2024001954A publication Critical patent/MX2024001954A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente descripción se proporcionan métodos, usos, y composiciones farmacéuticas de anticuerpos que se unen a la IL-13 humana ("anticuerpos anti-IL-13") para tratar la dermatitis atópica. También se proporcionan en la presente descripción regímenes de dosificación para los métodos y usos de los anticuerpos anti-IL-13 para tratar la dermatitis atópica.
MX2024001954A 2021-08-13 2022-08-12 Anticuerpos il-13 para el tratamiento de la dermatitis atopica. MX2024001954A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163232977P 2021-08-13 2021-08-13
US202163233544P 2021-08-16 2021-08-16
US202163247821P 2021-09-24 2021-09-24
US202263327539P 2022-04-05 2022-04-05
US202263343315P 2022-05-18 2022-05-18
PCT/US2022/074926 WO2023019260A1 (en) 2021-08-13 2022-08-12 Il-13 antibodies for the treatment of atopic dermatitis

Publications (1)

Publication Number Publication Date
MX2024001954A true MX2024001954A (es) 2024-03-01

Family

ID=83193459

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001954A MX2024001954A (es) 2021-08-13 2022-08-12 Anticuerpos il-13 para el tratamiento de la dermatitis atopica.

Country Status (8)

Country Link
EP (1) EP4384546A1 (es)
JP (1) JP2024531205A (es)
KR (1) KR20240043791A (es)
AU (1) AU2022326574A1 (es)
CA (1) CA3227401A1 (es)
IL (1) IL310706A (es)
MX (1) MX2024001954A (es)
WO (1) WO2023019260A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215769A1 (en) * 2022-05-05 2023-11-09 Dermira, Inc. Il-13 antibodies for the treatment of atopic dermatitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104013957B (zh) 2003-12-23 2016-06-29 泰勒公司 用新的抗il13单克隆抗体治疗癌症
WO2008112472A2 (en) 2007-03-09 2008-09-18 Eli Lilly And Company Delay mechanism for automatic injection device
US8734394B2 (en) 2010-03-01 2014-05-27 Eli Lilly And Company Automatic injection device with delay mechanism including dual functioning biasing member
FI3091029T3 (fi) 2011-10-31 2023-03-20 Hoffmann La Roche Anti-il13-vasta-aineformulaatioita
AU2013331603B2 (en) 2012-10-19 2016-05-19 Eli Lilly And Company Automatic injection device with trigger assembly
WO2016089864A1 (en) 2014-12-03 2016-06-09 Eli Lilly And Company Needle shield puller cap assembly
MX2017011486A (es) 2015-03-16 2018-06-15 Genentech Inc Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
RS64550B1 (sr) * 2016-09-23 2023-09-29 Hoffmann La Roche Upotreba il-13 antagonista za lečenje atopičnog dermatitisa

Also Published As

Publication number Publication date
IL310706A (en) 2024-04-01
KR20240043791A (ko) 2024-04-03
CA3227401A1 (en) 2023-02-16
WO2023019260A1 (en) 2023-02-16
JP2024531205A (ja) 2024-08-29
TW202323291A (zh) 2023-06-16
EP4384546A1 (en) 2024-06-19
AU2022326574A1 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
MX2022001607A (es) Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola.
MX2024000830A (es) Anticuerpos il-13 para el tratamiento de la dermatitis atopica.
MX2020005651A (es) Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
MX2020011546A (es) Anticuerpos anti-msr1 y metodos de uso de los mismos.
PH12021550020A1 (en) High-affinity, isoform-selective tgf#1 inhibitors and use thereof
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
ZA202202363B (en) Antibodies against ilt2 and use thereof
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
MX2021015337A (es) Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2019015071A (es) Composiciones y metodos para tratar tauopatias.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2023003993A (es) Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.
MX2021007453A (es) Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo.
MX2024001954A (es) Anticuerpos il-13 para el tratamiento de la dermatitis atopica.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
EP4023674A3 (en) Anti-il-22r antibodies
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
NZ762312A (en) Anti-pacap antibody
MX2021008716A (es) Metodo para tratar dolor de osteoartritis al administrar resiniferatoxina.
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
CR20230525A (es) Anticuerpos anti-cd20 y estructuras car-t
MX2022001781A (es) Metodos de terapia celular.